2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1342

Use of Immune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Diseases: A Systematic Review of Case Reports
Abstract Number: 14L

Use of Intravenous Epoprostenol As a Treatment for the Digital Vasculopathy Associated with the Scleroderma Spectrum of Diseases
Abstract Number: 2944

Use of Muscle Biopsies for the Diagnosis of Systemic Vasculitis in a Rheumatology Service
Abstract Number: 789

Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development
Abstract Number: 2442

Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Abstract Number: 995

Use of Opiate Diminished the Treatment Benefits of Motivational Interviewing for Fibromyalgia
Abstract Number: 501

Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis
Abstract Number: 1159

Use of Rheumatology-Specific Patient Navigators for DMARD Adherence: Results from a Pilot Intervention
Abstract Number: 3062

Use of Script Concordance Testing to Evaluate the Efficacy of a Web-Based Module on Gout: Three Years of Experience
Abstract Number: 1338

Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Abstract Number: 3254

Use of the Short Valued Life Activities Scale in People with Systemic Sclerosis
Abstract Number: 417

Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis
Abstract Number: 390

Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India
Abstract Number: 502

Use, Usability and Feasibility of a Mapp for Patients with Rheumatoid Arthritis – First Results
Abstract Number: 2888

Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].